Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
---|---|---|---|
USD 3.11 Billion | USD 6.23 Billion | 7.8% | 2024 |
The global brain tumor diagnosis and treatment market size was worth around USD 3.11 Billion in 2024 and is predicted to grow to around USD 6.23 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 7.8% between 2025 and 2034. The report analyzes the global brain tumor diagnosis and treatment market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the brain tumor diagnosis and treatment industry.
When abnormal cells develop within the brain, they produce a brain tumor. The growing geriatric population and increased prevalence of brain tumors are significant factors driving the global growth of the brain tumor diagnosis and treatment market. Additionally, the increasing number of technical developments, as well as rising levels of investment in research and development activities, would contribute to the expansion of the brain tumor diagnosis and treatment market during the anticipated period. The growing burden of brain tumors, increased awareness, and increased R&D on cancer therapies all contribute to the expansion. Rising R&D initiatives to develop immunotherapeutics to treat brain cancers, as well as ongoing government support to develop new therapies, are expected to drive segment growth throughout the projection period. Moreover, government measures to improve healthcare infrastructure, together with joint efforts by pharmaceutical companies to raise knowledge about the availability of various medications, are likely to fuel market expansion throughout the projection period.
The brain is the most important organ of the human body, which consists of nerve cells and other supportive tissues. The development of cancerous cells in the brain is known as a brain tumor. There are two major types of brain tumors, namely secondary brain tumors and primary brain tumors. Primary brain tumors can either be malignant or benign, whereas secondary brain tumors are metastatic, i.e., they can spread to other organs as well.
Product Demand will be driven by the Rising Incidence and Prevalence of Neurological Disorders
The rapidly increasing frequency of neurological illnesses in adults and children around the world is fueling market expansion. Brain illnesses, which include psychiatric, developmental, and neurodegenerative diseases, are a growing cause of morbidity worldwide. This can be attributable partly to the growing geriatric population. According to the American Medical Association (AMA), by 2050, more than 20% of the world population would be over the age of 65. Furthermore, by 2030, at least 60% of those aged 65 and up will be living with more than one chronic illness. As a result, the increased prevalence of various neurological disorders worldwide is a major driver driving the growth of the brain tumor medications market.
The Increasing Use of Targeted Therapies Will Restriction Market Growth
The increasing use of tailored medicines will be a big impediment. Cancer medications that target cancer cells without hurting normal cells are known as targeted therapies. When compared to traditional chemotherapy and radiation therapy procedures, targeted therapy has proven to be more effective and has fewer side effects. As a result, the growing adoption of these therapies is predicted to disrupt the revenue generated by traditional brain tumor medications, hampering the market's expansion over the forecast period.
The brain tumor diagnosis and treatment market are segregated based on diagnosis, treatment, and product type.
By diagnosis, the market is classified into MRI, CT Scan, PET-CT Scan, EEG, Molecular Testing, and Others. It has been highlighted that CT-Scans continue to be the most recommended method of brain cancer diagnosis, owing to their capacity to accurately discern between bone masses and elaborate soft tissues, as well as the possibility to capture 3D images in a series from several angles. Furthermore, future technical improvements in new mobile CT-Scan devices are projected to contribute to the growth of the CT-Scan diagnosis segment throughout the forecast period.
By treatment, the market is classified into surgery, radiation therapy, radiosurgery, chemotherapy, targeted drug therapy, and immunotherapy. The immunotherapy market is expected to expand rapidly. Immunotherapy is a method of treating disease by either activating or inhibiting the immune system. Vaccines are an exciting new type of immunotherapy that activates the immune system to combat cancer. Immunotherapy has been shown to be beneficial in the treatment of glioblastoma multiforme, the most common primary malignant brain tumor in adults. Thus, increased R&D initiatives to develop immunotherapeutics to treat brain tumors, as well as ongoing government support to develop chance therapies, are expected to boost industry expansion throughout the projection period.
Report Attributes | Report Details |
---|---|
Report Name | Brain Tumor Diagnosis and Treatment Market |
Market Size in 2024 | USD 3.11 Billion |
Market Forecast in 2034 | USD 6.23 Billion |
Growth Rate | CAGR of 7.8% |
Number of Pages | 168 |
Key Companies Covered | GE Healthcare, Merck & Co. Inc., AstraZeneca, Carestream Health, Philips Healthcare, Siemens Healthcare Private Limited, Shimadzu Corporation, Hitachi Medical Systems, Pfizer.Inc, Toshiba Medical Systems, and others. |
Segments Covered | By Diagnosis, By Treatment, By Product Type, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, The Middle East and Africa (MEA) |
Base Year | 2024 |
Historical Year | 2020 to 2023 |
Forecast Year | 2025 - 2034 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
The market for brain tumor diagnostics and therapy is dominated by North America. This region's dominance in this market can be attributed to the greater diagnostic rate of malignancies such as glioblastoma in the United States. Greater access to advanced therapy is also expected to contribute to the region's supremacy. Another important aspect influencing the regional market's expansion is the frequent introduction of new goods, paired with the region's strong presence of significant companies.
Europe will hold the second-largest market share in the forecast period, due to increased R&D funding and investments in the development of novel brain cancer drugs. This, together with vigorous government initiatives to raise awareness and access to brain tumor treatment, is expected to drive the growth of the brain tumor market throughout the forecast period. In addition, increased demand for oncology medications, rising brain cancer prevalence, and an aging population is driving the regional market.
Some of the main competitors dominating the
By Diagnosis Type
By Treatment Type
By Prod uct Type
By Region
FrequentlyAsked Questions
The global brain tumor diagnosis and treatment market is expected to grow due to increasing healthcare expenditure, rising prevalence of brain tumors, advancements in diagnostic imaging and treatment technologies, and growing awareness of early detection and personalized therapies.
According to a study, the global brain tumor diagnosis and treatment market size was worth around USD 3.11 Billion in 2024 and is expected to reach USD 6.23 Billion by 2034.
The global brain tumor diagnosis and treatment market is expected to grow at a CAGR of 7.8% during the forecast period.
North America is expected to dominate the brain tumor diagnosis and treatment market over the forecast period.
Leading players in the global brain tumor diagnosis and treatment market include GE Healthcare, Merck & Co. Inc., AstraZeneca, Carestream Health, Philips Healthcare, Siemens Healthcare Private Limited, Shimadzu Corporation, Hitachi Medical Systems, Pfizer.Inc, Toshiba Medical Systems, among others.
The report explores crucial aspects of the brain tumor diagnosis and treatment market, including a detailed discussion of existing growth factors and restraints, while also examining future growth opportunities and challenges that impact the market.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed